Neurogenesis

Health Direct Introduces AminoMind, The First-Of-Its-Kind Nootropic Collagen

Retrieved on: 
Thursday, March 14, 2024
Dopamine, Fatigue, Brain, Nutrient, Mevalonate pathway, Learning, Serotonin, Science, BDNF, Memory, Research, Nitric oxide, Neurogenesis, Collagen, Water, Blood, Medical imaging

IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind. This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients. BDNF creates new brain cells (neurogenesis) and supports new neural pathways and adaptation (neuroplasticity.)

Key Points: 
  • IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind.
  • This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients.
  • CollaBrain's dipeptides are the only collagen clinically shown to improve brain health and support BDNF production.
  • It's about supporting your brain's structure," says Jim Caras, founder of Health Direct, "Imagine pouring very expensive water into a bucket with holes.

Lifespan Vision Ventures invests in Bolden Therapeutics

Retrieved on: 
Tuesday, January 9, 2024
Partnership, Neurogenesis, Sympathetic nervous system, Alzheimer's disease, Longevity, Therapy, DSM-IV codes, Pharmaceutical industry

NORWALK, Conn., Jan. 9, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm that specializes in funding longevity biotech breakthroughs, today announced an investment in Bolden Therapeutics, Inc.

Key Points: 
  • NORWALK, Conn., Jan. 9, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm that specializes in funding longevity biotech breakthroughs, today announced an investment in Bolden Therapeutics, Inc.
  • This biotechnology company is developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system diseases.
  • Andrew Worden, Founding Partner at LifeSpan Vision Ventures, stated: "We're excited to partner with Bolden Therapeutics and enthusiastic about the potential of their promising results in advancing treatment options for Alzheimer's disease and other age-related neurodegenerative conditions.
  • "We are extremely excited to have Lifespan Vision Ventures as part of Team Bolden," said Johnny Page, co-founder and CEO of Bolden Therapeutics, Inc. "The next several months are a crucial time for the company and Lifespan's partnership represents a fantastic step towards achieving our goal of developing therapies to combat neurological diseases."

Lifespan Vision Ventures invests in Bolden Therapeutics

Retrieved on: 
Tuesday, January 9, 2024
Partnership, Neurogenesis, Sympathetic nervous system, Alzheimer's disease, Longevity, Therapy, DSM-IV codes, Pharmaceutical industry

NORWALK, Conn., Jan. 9, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm that specializes in funding longevity biotech breakthroughs, today announced an investment in Bolden Therapeutics, Inc.

Key Points: 
  • NORWALK, Conn., Jan. 9, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm that specializes in funding longevity biotech breakthroughs, today announced an investment in Bolden Therapeutics, Inc.
  • This biotechnology company is developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system diseases.
  • Andrew Worden, Founding Partner at LifeSpan Vision Ventures, stated: "We're excited to partner with Bolden Therapeutics and enthusiastic about the potential of their promising results in advancing treatment options for Alzheimer's disease and other age-related neurodegenerative conditions.
  • "We are extremely excited to have Lifespan Vision Ventures as part of Team Bolden," said Johnny Page, co-founder and CEO of Bolden Therapeutics, Inc. "The next several months are a crucial time for the company and Lifespan's partnership represents a fantastic step towards achieving our goal of developing therapies to combat neurological diseases."

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Retrieved on: 
Thursday, December 21, 2023
Bar-Ilan University, Cocaine, Depression, FDA, Crime, PLUR, Pharmaceutics, Plural, PLX, Brain, Drug, Research, Rat, BIRAD, PTSD, Anxiety, U.N, Neurogenesis, Cell, Neuron, PAD, Pharmaceutical industry

Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.

Key Points: 
  • Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.
  • The agreement stems from a collaboration between Pluri and Bar-Ilan University researchers that presented compelling findings.
  • The studies evaluated PLX-PAD cells’ efficacy in treating cocaine addiction in animal models.
  • Across North America and Europe, demand for treatment has steadily increased over the last decade, according to the U.N. Office on Drugs and Crime.

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Retrieved on: 
Wednesday, November 15, 2023
Molecule, ISCB Senior Scientist Award, Annual general meeting, HGF, Cell proliferation, Athira Pharma, Neuron, Microglia, LPS, Oxidative stress, Neurogenesis, Neuroinflammation, Society, Pharmaceutical industry, Medical imaging, Neuroscience, Neurotrophic factors

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.

Key Points: 
  • “We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.
  • “Our latest data demonstrate consistent neuroprotective effects of fosgonimeton and provide insights into the mechanisms by which it preserves neurons from degeneration and reduces neuroinflammation.
  • Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented preclinical research demonstrating the cellular mechanisms by which fosgonimeton induces anti-inflammatory effects in BV2 microglia cells.
  • The anti-inflammatory effects of fosgonimeton demonstrated in these models suggest it may have the potential to help reduce neuroinflammation, a key pathological feature of several neurodegenerative diseases.

UCSF QBI and the Department of Psychiatry and Behavioral Sciences Announce Breakthrough Research Findings in the Molecular Understanding of Autism

Retrieved on: 
Monday, December 4, 2023
Research, Neurology, Genetics, Clinical Trials, Biometrics, Biotechnology, General Health, Pharmaceutical, Health, Science, Sequence, ASD, Anatomy, School, Associate, Brain, Chemistry, Senior, Gladstone Institutes, Gene, Proteomics, Mass spectrometry, Quantitative Biosciences Institute, Spectrum, Protein, UCSF, Doctor of Philosophy, DSM-IV codes, Neuron, Psychiatry, University, Therapy, MD, Behavioural sciences, UCL, Neurogenesis, CRISPR, BioRxiv, SSD, Manuscript, QBI, Vaccine, Pharmacy, Neurosurgery

The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).

Key Points: 
  • The Quantitative Biosciences Institute (QBI), in collaboration with the Department of Psychiatry and Behavioral Sciences, at the University of California, San Francisco (UCSF), today reported new breakthrough research findings in the understanding of autism spectrum disorder (ASD).
  • Belinda Wang, MD, Ph.D., Rasika Vartak, Ph.D., Fima Zaltsman, Ph.D., and Zun Zar Chi Naing, Ph.D. are co-first authors of the manuscript.
  • Their findings provide unprecedented insights into the molecular mechanisms of a subset of individuals with ASD who carry specific genetic mutations, serving as a new platform for desperately needed therapeutics development.
  • QBI’s convergent biological systems approach that formed the basis of this study can be applied to virtually any disease area.

A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 clinical trial of Sovateltide for the treatment of acute cerebral ischemic stroke patients

Retrieved on: 
Monday, October 2, 2023
Neuron, Therapy, Marketing, Neurogenesis, Safety, Stroke, Brain, Trial of the century, Blood, US, NIHSS, Sun Pharma, SPA, Nursing care plan, RTPA, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Pharmaceutical industry, Patient

The protocol is titled "The Safety And Efficacy Of Sovateltide In Patients With Acute Cerebral Ischemic Stroke."

Key Points: 
  • The protocol is titled "The Safety And Efficacy Of Sovateltide In Patients With Acute Cerebral Ischemic Stroke."
  • This SPA agreement by the FDA provides a clear-cut regulatory path for sovateltide, our first-in-class drug for acute cerebral ischemic stroke.
  • The narrow time window of rtPA of 4.5 hours limits its use in most patients with cerebral ischemic stroke.
  • This includes cerebral ischemic stroke patients who completely recovered from earlier episodes before having a new or fresh stroke.

Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India

Retrieved on: 
Thursday, September 14, 2023
BSE, Reuters, Therapy, Marketing, UK India Business Council, Neurogenesis, B.I, Stroke, Quality of life, Dayanand Medical College & Hospital, Sun Pharma, NSE, Incidence, Patient, NIHSS, RTPA, MRS, Disease, Mortality, Nursing care plan, Hospital, Neuro, Death, Generic drug, Pharmaceutical industry

Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke.

Key Points: 
  • Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke.
  • As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide).
  • Pharmazz will be entitled to upfront and milestone payments, including royalties.
  • Kirti Ganorkar, CEO – India Business, Sun Pharma said, “The Phase 3 clinical trial for Tyvalzi™ conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders

Retrieved on: 
Thursday, July 27, 2023
Neuroprotection, Partnership, Neurotransmission, Drug development, Neurogenesis, Disease, University, DSM-IV codes, SCO-spondin, ALS, Research, Multimedia, CNS, Central nervous system, Multiple sclerosis, MS, HIV disease progression rates, CM, Patient, Amyotrophy, Central nervous system disease, Apoptosis, Parkinson's disease, Artificial intelligence, AI, Ecosystem, Safety, Fine chemical, Pharmaceutical industry, Medical device

Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.

Key Points: 
  • Mechanistic CNS models are designed to simulate the physiological and pathological aspects of CNS disorders, providing insights into the disease mechanisms and potential therapeutic interventions.
  • Given that Axoltis drug candidate NX210c targets these features, the collaboration with InSilicoTrials holds great promise for supporting CNS functions in a wide range of neurological and neurodegenerative conditions.
  • "We are thrilled to collaborate with Axoltis in our shared mission to advance therapeutic solutions for neurological disorders," said Luca Emili, CEO of InSilicoTrials.
  • Axoltis Pharma is a French biopharmaceutical company dedicated to developing a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.